Oral tofacitinib helps in alopecia areata in children

Published On 2021-12-25T16:05:27+05:30 | Updated On 25 Dec 2021 10:35 AM GMT

Overview

A recent study in the journal Pediatric Dermatology showed oral tofacitinib to be clinically effective and well-tolerated in the majority of pediatric patients with alopecia areata (AA).

Alopecia areata is an autoimmune disorder characterized by the loss of hair, often in well-demarcated areas. While its pathogenesis is not well understood, it is known that CD8 T cell-mediated destruction of the hair follicle occurs. Several therapies have been utilized with variable results but there is no definitive therapy for AA. Oral tofacitinib, a JAK inhibitor, has been shown to be effective and well-tolerated for the treatment of AA in adults. However, few studies have examined the clinical efficacy and tolerability of oral tofacitinib for the treatment of pediatric AA.

For more details, check out the full story on the link below:

Oral tofacitinib effective for treating alopecia areata in children: Study

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751